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Antimicrobial peptides (AMPs) are promising templates for the development of novel
antibiofilm drugs. Despite the large number of studies on screening and optimization
of AMPs, only a few of these evaluated the antibiofilm activity in physiologically
relevant model systems. Potent in vitro activity of AMPs often does not translate
into in vivo effectiveness due to the interference of the host microenvironment with
peptide stability/availability. Hence, mimicking the complex environment found in biofilm-
associated infections is essential to predict the clinical potential of novel AMP-based
antimicrobials. In the present study, we examined the antibiofilm activity of the semi-
synthetic peptide lin-SB056-1 and its dendrimeric derivative (lin-SB056-1)2-K against
Pseudomonas aeruginosa in an in vivo-like three-dimensional (3-D) lung epithelial cell
model and an in vitro wound model (consisting of an artificial dermis and blood
components at physiological levels). Although moderately active when tested alone, lin-
SB056-1 was effective in reducing P. aeruginosa biofilm formation in association with
3-D lung epithelial cells in combination with the chelating agent EDTA. The dimeric
derivative (lin-SB056-1)2-K demonstrated an enhanced biofilm-inhibitory activity as
compared to both lin-SB056-1 and the lin-SB056-1/EDTA combination, reducing the
number of biofilm-associated bacteria up to 3-Log units at concentrations causing less
than 20% cell death. Biofilm inhibition by (lin-SB056-1)2-K was reported both for the
reference strain PAO1 and cystic fibrosis lung isolates of P. aeruginosa. In addition, using
fluorescence microscopy, a significant decrease in biofilm-like structures associated
with 3-D cells was observed after peptide exposure. Interestingly, effectiveness of
(lin-SB056-1)2-K was also demonstrated in the wound model with a reduction of
up to 1-Log unit in biofilm formation by P. aeruginosa PAO1 and wound isolates.
Overall, combination treatment and peptide dendrimerization emerged as promising
strategies to improve the efficacy of AMPs, especially under challenging host-mimicking
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conditions. Furthermore, the results of the present study underlined the importance
of evaluating the biological properties of novel AMPs in in vivo-like model systems
representative of specific infectious sites in order to make a more realistic prediction
of their therapeutic success, and avoid the inclusion of unpromising peptides in animal
studies and clinical trials.
Keywords: antimicrobial peptides, dendrimeric peptide, combination treatment, biofilm, Pseudomonas
aeruginosa, 3-D lung epithelial cell model, artificial wound model
INTRODUCTION
The opportunistic pathogen Pseudomonas aeruginosa is known
to play a role in many types of infections, including lung
infections, wound infections, otitis media and medical device-
associated infections (Taylor et al., 2014; Rybtke et al., 2015).
P. aeruginosa infections range from minor external infections
to serious and life-threatening conditions, such as in individuals
with CF (Gellatly and Hancock, 2013). Intrinsic and acquired
resistance to many conventional antibiotics makes the treatment
of P. aeruginosa infections particularly challenging (Breidenstein
et al., 2011). The ability of P. aeruginosa to form biofilms further
complicates the problem of antimicrobial resistance causing
high rates of failure in antibiotic therapy and chronic infection
of the host (Parsek and Singh, 2003; Mulcahy et al., 2014).
Therefore, the identification of novel antimicrobial agents that
can effectively suppress P. aeruginosa biofilm-related infections
is a research priority.
Over the last years, AMPs have gained increasing attention
as candidates for the development of innovative antimicrobial
drugs. Due to their main mechanism of action, which relies
on the permeabilization of bacterial membranes, AMPs exhibit
broad-spectrum activity, a low tendency to induce resistance,
and a high potential to target metabolically dormant cells that
are found at elevated rate within microbial biofilms (Batoni
et al., 2016b; Grassi et al., 2017a). A number of AMPs have
been tested for their antibiofilm activity (BaAMPs database1),
demonstrating a variable effectiveness in interfering with the
different stages of biofilm formation (Di Luca et al., 2015; de la
Fuente-Núñez et al., 2016). Despite the large number of studies
reporting the screening and optimization of AMPs, only a few
of these evaluated the antibiofilm activity in clinically relevant
model systems (Lashua et al., 2016; Crabbé et al., 2017; de Breij
et al., 2018). Nevertheless, the specific environmental conditions
found at the site of infection have been shown to influence
both biofilm architecture and susceptibility and to interfere
with the activity and stability of AMPs (Bjarnsholt et al., 2013;
Crabbé et al., 2017). For this reason, potent in vitro activity of
AMPs does not necessarily translate into in vivo effectiveness,
resulting in a limited predictive value (Mardirossian et al., 2017;
Abbreviations: AMP, antimicrobial peptide; BB, Bolton broth; CF, cystic fibrosis;
CFUs, colony-forming units; Col, collagen; EDTA, ethylenediaminetetraacetic
acid; FBS, fetal bovine serum; HA, hyaluronic acid; HBSS, Hanks’ balanced
salt solution; hRBCs, human red blood cells; LB, Luria-Bertani broth; LDH,
lactate dehydrogenase; MHB, Mueller-Hinton broth; MIC, minimal inhibitory
concentration; PSS, physiological saline solution; RWV, rotating-wall vessel; TSA,
tryptone soy agar; TSB, tryptone soy broth; WLM, wound-like medium.
1www.baamps.it
Dostert et al., 2018). Therefore, the screening of AMPs in
conditions mimicking the host microenvironment and the in vivo
host–pathogen interactions represents an essential step to assess
the clinical potential of novel AMP-based antimicrobials.
The semi-synthetic peptide lin-SB056-1 has been recently
designed as a beta-strand with a perfect pattern of alternating
hydrophilic and hydrophobic residues in the primary structure
in order to maximize bacterial membrane interaction and
killing (Manzo et al., 2015). The regular amphipathic profile of
lin-SB056-1 significantly enhanced the antibacterial properties
of the peptide, which displayed a rapid and strong activity
against a broad spectrum of Gram-positive and Gram-negative
bacteria, including multidrug-resistant clinical isolates of
P. aeruginosa (Maisetta et al., 2017). In addition to exerting
a marked antibiofilm activity in standard conditions, lin-
SB056-1 in combination with EDTA demonstrated the ability
to almost completely inhibit the formation of P. aeruginosa
biofilm-like structures in an artificial sputum medium
mimicking the lung environment of CF patients (Maisetta
et al., 2017). Since dendrimeric peptides are known to exhibit
enhanced antimicrobial activity as compared to their monomeric
counterparts (Lind et al., 2015; Pires et al., 2015), lin-SB056-1
has been further optimized by generating a two-branched
polypeptide with a lysine linker and a lipidic tail (den-SB056-1)
(Batoni et al., 2016a). Interestingly and differently from the
monomeric structure, den-SB056-1 has been demonstrated
to preserve high affinity for negatively charged membranes
and to retain its antibacterial activity even in the presence of
physiological salt concentrations (Batoni et al., 2016a). Since
the inhibition of AMPs by salts represents a severe limitation
to their applicability (Maisetta et al., 2008), maintenance
of activity at high ionic strength makes the dendrimeric
derivative particularly promising for the use in physiological
conditions (Polcyn et al., 2013). In the current study, a
slightly different dimeric derivative of lin-SB056-1, referred
to as (lin-SB056-1)2-K, has been obtained starting from
den-SB056-1 through the elimination of the lipidic moiety.
Indeed, a recent study has reported that the lipidic tail does
not play a fundamental role in the membrane-binding affinity
as well as in the antimicrobial properties of the peptide
(Manzo et al., 2016).
In the present study, combination treatment (i.e., lin-SB056-1
used in combination with EDTA) and peptide dendrimerization
[i.e., design of (lin-SB056-1)2-K] were investigated as two
promising strategies to improve the antibacterial and antibiofilm
activity of lin-SB056-1 against P. aeruginosa under in vivo-
like conditions. In particular, the antimicrobial properties of
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the lin-SB056-1/EDTA combination and/or (lin-SB056-1)2-K
were assessed in two representative model systems of biofilm-
associated infections, namely an in vivo-like three-dimensional
(3-D) lung epithelial cell model and an artificial wound
model. Organotypic 3-D lung models have been previously
developed by using the RWV bioreactor technology, which
allows to replicate aspects of the in vivo lung infection with
P. aeruginosa biofilms (Carterson et al., 2005; Barrila et al.,
2010; Crabbé et al., 2014, 2017). In order to mimic chronic
wound infections, we exploited an in vitro wound model
reflecting the nutritional conditions found in wound beds, and
resembling the actual surface on which bacterial aggregates are
formed in vivo (Brackman and Coenye, 2016; Trivedi et al.,
2017). Overall, the results demonstrated the ability of the
lin-SB056-1/EDTA combination to retain its biofilm-inhibitory
activity in the presence of the host cellular component that
is known to markedly influence the effectiveness of both
antibiotics and AMPs (Moreau-Marquis et al., 2008; Crabbé et al.,
2017). Furthermore, the dendrimeric peptide (lin-SB056-1)2-K
displayed an enhanced ability in inhibiting P. aeruginosa biofilm
formation as compared to both lin-SB056-1 and the lin-SB056-
1/EDTA combination, thereby underlining the importance of
the rational peptide optimization to obtain valid templates
to be developed as novel antibiofilm agents. Importantly, the
present study highlighted the need of including physiologically
relevant model systems in the preclinical testing of candidate
antibiofilm peptides in order to assess their potential, but also
their limitations.
MATERIALS AND METHODS
AMPs and EDTA
Lin-SB056-1 (KWKIRVRLSA-NH2) and (lin-SB056-1)2-K
([KWKIRVRLSA]2-K) were synthetized by Peptide Protein
Research (Fareham, England). Analysis of the synthetic
peptides by high performance liquid chromatography and mass
spectrometry revealed purity over 98%. Peptides were diluted in
milli-Q water to obtain a stock solution of 2 mg/mL and stored at
−80◦C. Disodium EDTA was purchased from Sigma-Aldrich (St.
Louis, MO, United States). A stock solution of EDTA (50 mM,
pH 8) was prepared in milli-Q water, sterilized by filtration and
stored at 4◦C.
Bacterial Strains and Culture Conditions
The reference strain P. aeruginosa PAO1 (ATCC 15692) was
used in this study as well as clinical isolates of P. aeruginosa
(AA2 and AA44) from the lungs of patients with CF (Cullen
et al., 2015). P. aeruginosa burn wound isolates (2091 and
2549) were obtained from Ghent University Hospital (Ghent,
Belgium) (Zhang et al., 2018). For experiments involving
fluorescence imaging of host-associated biofilms, the previously
reported GFP-expressing strain of P. aeruginosa PAO1 was
used (Crabbé et al., 2017). All strains were stored in a
cryovial bead storage system (Microbank, Pro-Lab Diagnostics,
Metropolitan Borough of Wirral, United Kingdom) at −80◦C.
For the preparation of the inoculum, beads from the frozen
cultures were spread on TSA (LabM) and incubated overnight
at 37◦C. Liquid cultures were prepared starting from colonies
isolated on agar plates. For all studies, P. aeruginosa PAO1,
GFP-tagged P. aeruginosa PAO1 and P. aeruginosa clinical
isolates from CF patients (AA2 and AA44) were aerobically
cultured in LB at 37◦C, 250 rpm. P. aeruginosa clinical isolates
from wounds (2091 and 2549) were aerobically grown in TSB
(LabM) at 37◦C.
Determination of Minimal Inhibitory
Concentration (MIC)
The susceptibility of P. aeruginosa PAO1 and CF clinical isolates
to lin-SB056-1 and (lin-SB056-1)2-K was assessed in terms of
MIC values according to the standard microdilution method
(Clinical and Laboratory Standards Institute [CLSI], 2018).
Bacteria were grown in Mueller-Hinton Broth (MHB, Oxoid,
Basingstoke, United Kingdom) until exponential phase and
diluted in the same medium to reach a final density of 1 × 107
CFU/mL. A volume of 10 µL of the bacterial suspensions was
added to 90 µL of MHB in the absence (viability control) or
in the presence of the peptides at different concentrations (1.2–
77 µM). MIC values of both peptides were also determined in the
culture medium used to grow 3-D lung epithelial cells (i.e., GTSF-
2 medium, as described in Section “Biofilm Model Systems”).
MIC values were defined as the lowest concentration of each
peptide resulting in the complete inhibition of visible growth after
24 h of incubation at 37◦C.
Bactericidal Activity in GTSF-2 Medium
Bactericidal activity of lin-SB056-1, used alone and in
combination with EDTA, was evaluated against P. aeruginosa
PAO1 in GTSF-2 medium, as described previously (Maisetta
et al., 2017). Bacteria were grown in LB until exponential
phase and diluted in GTSF-2 medium to reach a final density
of 1 × 107 CFU/mL. A volume of 10 µL of the bacterial
suspensions was added to 90 µL of GTSF-2 medium containing
lin-SB056-1 (19.25 and 38.5 µM), EDTA (0.3–1.25 mM) and
different peptide/EDTA combinations. Bacteria suspended in
GTSF-2 medium were used as viability control. Samples were
incubated statically for 1.5 h (37◦C, 5% CO2), subsequently
diluted 10-fold in a PSS (0.9% NaCl) and plated on TSA for the
CFU count.
Biofilm Model Systems
A 3-D lung epithelial cell model and an artificial wound
model were exploited to assess the biofilm-inhibitory activity
of the AMPs under investigation. The 3-D lung model was
generated by growing the human adenocarcinoma alveolar
epithelial cell line A549 (ATCC CCL-185) on microcarrier beads
in RWV bioreactors (Synthecon, Houston, TX, United States), as
previously described (Carterson et al., 2005; Crabbé et al., 2017).
3-D cultures were generated in GTSF-2 medium (GE Healthcare,
Diegem, Belgium) supplemented with 10% heat-inactivated FBS
(Thermo Fisher Scientific, Waltham, MA, United States) and
1% penicillin/streptomycin (Thermo Fisher Scientific) and were
used for infection studies after 11–14 days of culture in the
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RWV (37◦C, 5% CO2). Immediately prior to use, 3-D A549
cells were washed once with HBSS and resuspended in GTSF-
2 medium (without FBS and antibiotics) at a final density of
1× 106 cells/mL.
The artificial wound model included a dermis-like scaffold
and blood components at physiological concentrations.
A two-layered artificial dermis composed of HA (Lifecore
Biomedical, Chaska, MN, United States) and collagen
(type-I collagen from rat tail) (Col; Sigma-Aldrich) with
dimensions of approximately 1 cm3 was prepared as previously
reported (Brackman et al., 2016). The upper layer of the
artificial dermis consisted of chemically cross-linked high-
molecular-weight HA (HMW-HA), while the lower layer
was prepared from a mixed solution of HMW-HA, low-
molecular-weight HA (LMW-HA) and heat-denatured Col.
The biphasic spongy sheet was obtained by lyophilisation,
subsequently irradiated with a UV lamp to induce cross-linking
between Col molecules and finally sterilized at 110◦C for
1 h. At the time of use, artificial dermis was immersed into
a WLM consisting of BB (LabM) supplemented with 50%
heparinized bovine plasma (Sigma-Aldrich) and 5% freeze-
thaw laked horse blood (Biotrading, Mijdrecht, Netherlands)
(Brackman et al., 2016).
Cytotoxicity in 3-D Lung Epithelial Cell
Model
Cytotoxicity of the tested compounds toward 3-D A549 cells
was assessed by measuring the enzymatic activity of cytosolic
LDH released from dead cells. Upon maturation of the 3-
D aggregates (11–14 days), a volume of 250 µL of the 3-D
lung epithelial cells (containing 2.5 × 105 cells) was transferred
into flat-bottom 48-well plates. Lin-SB056-1 (9.6–77 µM), used
alone and in combination with EDTA (0.3–1.25 mM), and (lin-
SB056-1)2-K (9.6–77 µM) were added to the 3-D cells and
incubated statically for 4 h at 37◦C, 5% CO2. 3-D aggregates
incubated in GTSF-2 medium alone were used as negative
(cell viability) control, while cells lysed with 1% Triton-X100
served as positive (death) control. Following incubation, cell
culture medium was collected and centrifuged at 2500 × g for
15 min in order to remove cell debris. The amount of LDH
in 3-D cell supernatants was quantified using a LDH activity
assay kit (Sigma-Aldrich) following manufacturer’s instructions.
The cytotoxic effect was determined according to the following
formula: Cytotoxicity (%) = [(LDH activity tested compound – LDH
activity negative control)/(LDH activity positive control – LDH activity
negative control)]× 100.
Biofilm-Inhibitory Activity in 3-D Lung
Epithelial Cell Model
The ability of lin-SB056-1, alone and in combination with EDTA,
to inhibit biofilm formation in association with 3-D cells was
evaluated against P. aeruginosa PAO1. Biofilm-inhibitory activity
of (lin-SB056-1)2-K was assessed against both P. aeruginosa
PAO1 and an isogenic pair of early and late clinical CF strains
isolated from the same patient (AA2 and AA44) (Cullen et al.,
2015). Bacteria were cultured overnight in LB (37◦C, 250 rpm),
suspended in GTSF-2 medium and added to 3-D A549 cells
(2.5 × 105 cells/well) into 48-well plates at a multiplicity of
infection (MOI) of 15. Biofilm formation was determined in the
absence (negative control) or presence of different concentrations
of lin-SB056-1 (9.6–77 µM), used alone and in combination with
EDTA (0.3 and 0.6 mM), and (lin-SB056-1)2-K (9.6–77 µM).
After 4 h of incubation (37◦C, 5% CO2), host-associated biofilm
formation was quantified through plating and CFU counting
as described previously (Crabbé et al., 2017). To this end, 3-
D cells were transferred into new 48-well plates and rinsed
twice with HBSS (Thermo Fisher Scientific) in order to remove
non-attached bacteria. To assess bacterial adhesion to 3-D cells,
biofilms were exposed to 0.1% Triton X-100, disrupted by
vigorous pipetting, serially diluted in PSS and plated on TSA.
Light and Fluorescence Microscopy
The effect of the tested compounds on morphology and integrity
of 3-D A549 cells was determined through light microscopy using
EVOS XL Core Imaging System (Life Technologies, Carlsbad,
CA, United States). Qualitative evaluation of antibiofilm activity
against GFP-tagged P. aeruginosa PAO1 in the 3-D lung epithelial
cell model was performed by fluorescence microscopy using
EVOS FL Auto Imaging System (Life Technologies). Light and
fluorescence microscopy images were acquired with 20 and 40x
objectives (total magnification of 599 and 1200x, respectively)
and appropriate filter cubes. Imaging of 3-D aggregates was
carried out following 4 h of incubation with the tested
compounds both in the absence and presence of bacteria.
Hemolysis Assay
Hemolytic activity of lin-SB056-1 and (lin-SB056-1)2-K was
tested against hRBCs as previously described (Grassi et al.,
2017c). Briefly, a suspension of hRBCs (5%, v/v) was mixed with
various concentrations of the peptides (1.2 to 77 µM) into round-
bottom polystyrene 96-well microplates. hRBCs suspended in
PBS alone were used as negative control (0% hemolysis), while
cells lysed with 0.1% (v/v) Triton X-100 were taken as positive
control (100% hemolysis). After 1 h of incubation (37◦C, static),
microplates were centrifuged at 1000 × g for 10 min, 4◦C.
Supernatants were transferred into new plates and optical density
at 450 nm (OD450) was measured using a microplate reader.
The hemolytic activity was quantified according to the following
formula: Hemolysis (%) = [(OD peptide – OD negative control)/(OD
positive control – OD negative control)]× 100.
Biofilm-Inhibitory Activity in Artificial
Wound Model
The ability of (lin-SB056-1)2-K to inhibit biofilm formation in
the artificial wound model was evaluated against P. aeruginosa
PAO1 and two clinical isolates from wound infections. Bacteria
were cultured overnight in TSB (37◦C, static), washed and
diluted in PSS to a final density of 1 × 106 CFU/mL. Artificial
dermis was placed into flat-bottom 24-well plates and soaked
with 500 µL of WLM. A volume of 10 µL of the bacterial
suspension was spotted on the top of each artificial dermis.
Following inoculation, (lin-SB056-1)2-K at a final concentration
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of 19.25 µM (100 µL) was added to the artificial dermis. Finally,
additional WLM (400 µL) was added around the artificial dermis
in order to avoid dehydration and plates were incubated at 37◦C
for 16 h. Based on preliminary experiments, such incubation
time was found to ensure adequate P. aeruginosa biofilm
formation without significant degradation of the artificial dermis
by bacterial secreted factors. After the incubation, the artificial
dermis was rinsed once in PSS to remove non-adherent cells and
placed in glass tubes containing 10 mL of PSS. Biofilm-forming
bacteria were detached from the artificial dermis through three
cycles of vortexing (30 s) and sonication (30 s; Branson 3510,
Branson Ultrasonics Corporation, Danbury, CT, United States),
serially diluted in PSS and pour-plated on TSA to determine the
number of CFU.
Statistical Analysis
All the experiments were performed at least in biological
triplicate, unless otherwise specified. Statistical analysis was
carried out using SPSS statistics software, version 25 (SPSS,
Chicago, IL, United States). Normal distribution of the data was
verified using the Shapiro–Wilk test. In the case of normally
distributed data, differences between mean values were evaluated
with the Student’s t-test for independent samples. Non-normally
distributed data were analyzed using a Mann–Whitney test and
Kruskal–Wallis test followed by Bonferroni post hoc test. In
the case of combination studies, differences between the effect
of the lin-SB056-1/EDTA combination and the sum of the
effects of its individual components (i.e., lin-SB056-1 and EDTA)
were analyzed using a Student’s t-test for independent samples.
A p-value< 0.05 was considered statistically significant.
RESULTS
Bactericidal Activity of lin-SB056-1 in
Combination With EDTA in Host Cell
Culture Medium
It is known that culture media can strongly affect the biological
properties of AMPs (Dorschner et al., 2006; Ersoy et al., 2017).
Therefore, the bactericidal activity of lin-SB056-1, alone and in
combination with EDTA, was evaluated in the host cell culture
medium (i.e., GTSF-2 medium) in order to identify the most
promising peptide/EDTA combinations to be included in the
subsequent antibiofilm activity studies. The antibacterial activity
against planktonic P. aeruginosa PAO1 was assessed after 1.5 h
of incubation taking into account the rapid killing kinetics of
lin-SB056-1 (Maisetta et al., 2017). The peptide alone was able
to reduce the number of viable bacteria by 3-Log units at a
concentration of 38.5µM (Figure 1A). In addition, a significantly
increased bactericidal activity was observed when the peptide
was used in combination with sub-inhibitory concentrations
of EDTA (Figure 1B). In particular, the combination of lin-
SB056-1 at 38.5 µM with EDTA (0.3 to 1.25 mM) resulted in
the reduction of the initial bacterial inoculum to the limit of
detection (10 CFU/mL) (Figure 1A). A statistically significant
difference was also obtained by comparing the Log reduction
of the lin-SB056-1/EDTA combination with the sum of the
Log reductions caused by the individual compounds (data
not shown).
Cytotoxicity of lin-SB056-1 in
Combination With EDTA in the 3-D Lung
Epithelial Cell Model
The effect of lin-SB056-1, used alone and in combination
with EDTA, on host cell viability was evaluated in the 3-
D lung epithelial cell model. Lin-SB056-1 alone did not
significantly affect host cell viability at any of the tested
concentrations, as determined through the measurement of
LDH release (Figure 2A). Similarly, no cytotoxic effect was
observed when EDTA was used alone in the concentration
range 0.3–1.25 mM. When used in combination with EDTA,
the peptide exerted enhanced cytotoxicity toward 3-D cells
although the fraction of dead cells was below 22% for all
tested peptide/EDTA combinations, with the exception of the
combination of 38.5 µM lin-SB056-1 and 1.25 mM EDTA
(approximately 50% cell death) (Figure 2A). Furthermore, due
to its chelating properties, the effect of EDTA on host cell
adhesion was assessed through the microscopic observation of 3-
D aggregates. Although EDTA was non-toxic when used alone
(Figure 2A), at the concentration of 1.25 mM, it caused a
morphological change of 3-D structures with the appearance
of round-shaped cells and noticeable cell detachment from
the scaffolds (Figure 2B). Nevertheless, morphology of 3-D
cells treated with lower concentrations of EDTA (0.3 and
0.6 mM) was similar to the untreated control (Figure 2B), even
when used in combination with the peptide (data not shown).
Accordingly, subsequent biofilm studies were performed by
selecting peptide/EDTA combinations able to reduce the number
of planktonic bacteria by at least 3-Log units with as low as
possible effect on cell viability (less than 22% cell death) and
adhesion (i.e., lin-SB056-1 at 19.25 and 38.5 µM combined with
EDTA at 0.3 and/or 0.6 mM).
Biofilm-Inhibitory Activity of lin-SB056-1
in Combination With EDTA in the 3-D
Lung Epithelial Cell Model
The peptide/EDTA combinations selected according to
bactericidal activity and cytotoxicity studies were tested for
their ability to inhibit biofilm formation by P. aeruginosa PAO1
in the 3-D lung epithelial cell model after 4 h of incubation.
Incubation time for the evaluation of the antibiofilm activity
was selected taking into account that P. aeruginosa PAO1
is able to form microcolonies on the 3-D lung epithelium
starting from 2 h of incubation (Crabbé et al., 2017). When
assayed alone, lin-SB056-1 (38.5 µM) resulted in a decrease
of approximately 0.5 Log-unit (3.3 fold) in the number of
biofilm-forming bacteria compared to the untreated control
(Figure 3). Among all the tested combinations, the most
powerful biofilm-inhibitory effect in terms of viable count
reduction (approximately 1 Log [10 fold] as compared to the
control) was obtained by combining lin-SB056-1 at 38.5 µM with
EDTA at 0.3 and 0.6 mM (Figure 3). At such concentrations,
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FIGURE 1 | Bactericidal activity of lin-SB056-1, alone and in combination with EDTA, against planktonic cells of Pseudomonas aeruginosa PAO1 in GTSF-2 medium
after 1.5 h of incubation. (A) Bactericidal activity of the lin-SB056-1/EDTA combinations was assessed by CFU count. Control (CTRL) represents untreated bacteria.
A number of 10 CFU/mL was taken as detection limit. Data are reported as mean ± standard error of at least three independent experiments. (B) p-Values obtained
by one-way ANOVA followed by Bonferroni post hoc test; only statistically significant comparisons are reported.
a statistically significant reduction in the CFU number was
observed between the combination and the peptide or EDTA
used alone (Figure 3). A statistically significant difference
(p < 0.05, independent samples t-test) was also obtained
by comparing the Log reduction of the lin-SB056-1/EDTA
combination with the sum of the Log reductions caused by the
individual compounds.
Activity of (lin-SB056-1)2-K in the 3-D
Lung Epithelial Cell Model
The biofilm-inhibitory activity and cytotoxicity of lin-SB056-1
were compared to those exerted by its dendrimeric derivative
(lin-SB056-1)2-K in order to explore the possibility to obtain an
improved antibiofilm effect in the 3-D lung epithelial cell model.
The antibacterial activity of the two peptides was preliminarily
compared in terms of MIC values, evaluated in MHB and GTSF-
2 medium. Interestingly, although (lin-SB056-1)2-K was found to
exhibit 2 to 4-fold higher MIC values in MHB than lin-SB056-
1 against P. aeruginosa PAO1 and CF lung isolates (AA2 and
AA44), it exerted an enhanced antibacterial activity in GTSF-2
medium (Table 1). Accordingly, (lin-SB056-1)2-K demonstrated
a significantly improved ability to inhibit biofilm formation
by P. aeruginosa PAO1 as compared to its linear counterpart
in the 3-D lung epithelial cell model (Figure 4A). Although
dendrimerization of the peptide was associated with an overall
increase in cytotoxicity toward 3-D A549 cells (Figure 4B), (lin-
SB056-1)2-K at a concentration causing less than 20% cell death
(19.25 µM) (Figure 4B) reduced the number of biofilm-forming
bacteria by 2-Log units (100 fold) (Figure 4A). Thus, when
compared at the same cut-off of cytotoxicity (20% cell death)
(Figure 4B), the dendrimeric form of the peptide (at 19.25 µM)
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FIGURE 2 | Cytotoxicity of lin-SB056-1 and EDTA, used alone and in combination, toward 3-D lung epithelial cells after 4 h of incubation. (A) Cell viability was
evaluated by LDH-release assay. Control (CTRL) represents untreated 3-D cells. Data are reported as mean ± standard error of at least three independent
experiments. (B) Effect of EDTA on cell adhesion to microcarrier bead scaffolds was evaluated by optical microscopy. Images were obtained at a magnification of
1200×. White arrow indicates round-shaped cells detaching from the surface of microcarrier beads.
caused an additional 1.5-Log unit reduction in the CFU count as
compared to its linear counterpart (at 38.5 µM) (Figure 4A).
Higher levels of cytotoxicity of the dendrimeric
peptide over the monomeric counterpart were also
observed in a standard hemolysis assay. Nevertheless, at
concentrations exerting significant antibiofilm activity (up to
19.25 µM), (lin-SB056-1)2-K caused less than 5% hemolysis
(Supplementary Figure S1).
Importantly, (lin-SB056-1)2-K also exhibited a marked ability
to inhibit biofilm formation by an early (AA2) and a late (AA44)
clinical isolate of P. aeruginosa from a CF patient. In particular, at
the concentration of 19.25 µM, the peptide reduced the number
of CFU up to 3-Log units (1000 fold) as compared to the
untreated control (Figure 5).
Qualitative assessment of the antibiofilm activity of (lin-
SB056-1)2-K in the 3-D lung epithelial cell model was performed
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FIGURE 3 | Biofilm-inhibitory activity of lin-SB056-1, alone and in combination with EDTA, against P. aeruginosa PAO1 in the 3-D lung epithelial cell model after 4 h
of incubation. Control (CTRL) represents untreated bacteria. Data are reported as mean ± standard error of at least three independent experiments. ∗∗p < 0.01;
∗∗∗p < 0.001 (Kruskal–Wallis test followed by Bonferroni post hoc test).
by monitoring the formation of fluorescent biofilm-like
structures by GFP-producing P. aeruginosa PAO1. A remarkable
decrease in the amount of biofilm-like structures associated with
3-D lung epithelial cells was observed after the treatment with
(lin-SB056-1)2-K at 19.25 µM (Figure 6).
Biofilm-Inhibitory Activity of
(lin-SB056-1)2-K in Artificial Wound
Model
The efficacy of (lin-SB056-1)2-K against forming biofilms of
P. aeruginosa was also investigated in an in vitro chronic
wound model consisting of a dermis-like scaffold embedded in
physiological levels of blood components. At 19.25 µM, (lin-
SB056-1)2-K displayed a significant biofilm-inhibitory activity
against both P. aeruginosa PAO1 and the wound clinical isolate
2091, reducing the number of viable bacteria up to 1 Log-unit (10
fold) after 16 h of incubation (Figure 7). Although the peptide
resulted in a reduction of approximately twofold in the CFU
count of the clinical strain 2549, the difference did not reach
TABLE 1 | Minimal inhibitory concentration (MIC) values of lin-SB056-1 and
(lin-SB056-1)2-K against P. aeruginosa PAO1 and CF clinical isolates evaluated in
MHB and GTSF-2 medium.
lin-SB056-1 (lin-SB056-1)2-K
MHB GTSF-2 MHB GTSF-2
PAO1 4.8a 38.5 19.25 9.6
AA2 9.6 77 38.5 9.6
AA44 4.8 38.5 9.6 2.4
aConcentrations are expressed in µM.
statistical significance as compared to the control (p = 0.058,
independent samples t-test).
DISCUSSION
Over the last years, an increasing awareness of the role of
biofilms in the establishment of chronic infections has led
to a growing interest in the identification and development
of novel antibiofilm strategies. High tolerance of biofilms to
available antibiotics has stimulated interest in AMPs as potential
antibiofilm agents (Batoni et al., 2011; Di Luca et al., 2015; de
la Fuente-Núñez et al., 2016). Nevertheless, most of the studies
assessing the antibiofilm activity of candidate AMPs have been
performed using in vitro models in which the conditions are
very different from those found in vivo at the site of infection
(Lebeaux et al., 2013; Roberts et al., 2015). In particular, the
electrostatic interaction of AMPs with bacterial membranes can
be dramatically reduced by the presence of salts at physiological
levels, proteases, macromolecules of the body fluids as well as
host cells (Dorschner et al., 2006; Hancock and Sahl, 2006;
Maisetta et al., 2008). Furthermore, many of these in vitro models
rely on the formation of surface-attached biofilms characterized
by a biomass order of magnitude larger than in vivo biofilms.
Indeed, it has been reported that in vitro biofilms can reach
dimensions of approximately 1 to 10 cm2 with a thickness up to
300 µm, whereas biofilm aggregates in chronic infections have
been shown to mainly range from 5 to 200 µm in diameter
(Bjarnsholt et al., 2013). In addition, different gene expression
patterns and susceptibility to most antimicrobials have been
reported for in vitro and in vivo-like biofilms (Caceres et al.,
2014; Crabbé et al., 2017). For example, P. aeruginosa biofilms
formed on CF bronchial epithelial cells have been found to exhibit
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FIGURE 4 | Comparison of the biofilm-inhibitory activity and cytotoxicity of lin-SB056-1 and (lin-SB056-1)2-K in the 3-D lung epithelial cell model after 4 h of
incubation. (A) Biofilm-inhibitory activity against P. aeruginosa PAO1 was assessed by CFU count. Data are reported as mean ± standard error of at least three
independent experiments. ∗∗p < 0.01; ∗∗∗p < 0.001 (Kruskal–Wallis test followed by Bonferroni post hoc test). (B) Viability of 3-D lung epithelial cells was evaluated
by LDH-release assay. Data are reported as mean ± standard error of at least three independent experiments. ∗∗∗p < 0.001 (one-way ANOVA followed by
Bonferroni post hoc test).
enhanced tolerance to tobramycin as compared to biofilms grown
on plastic surfaces (Anderson et al., 2008; Moreau-Marquis et al.,
2008). Therefore, conclusions drawn from standard laboratory
techniques may not be directly translated to human infections,
and physiologically relevant biofilm model systems are desirable
as a complementary tool for the evaluation of novel AMP-based
antimicrobial agents (Pompilio et al., 2015; Bock et al., 2018;
Dostert et al., 2018).
To address this issue, we exploited an in vivo-like 3-D
lung epithelial cell model and an artificial wound model in
order to assess the therapeutic potential of the semi-synthetic
peptide lin-SB056-1 and its dendrimeric derivative (lin-SB056-
1)2-K in the context of P. aeruginosa biofilm infections. Besides
mimicking key aspects of the lung tissue, P. aeruginosa has
been previously reported to form biofilms in the 3-D lung
epithelial cell model (Crabbé et al., 2017), which is relevant
for the phenotype of this opportunistic pathogen found during
chronic lung infections (Alhede et al., 2011; Bjarnsholt et al.,
2013; Ciofu et al., 2015). Additionally, the presence of host cells
has been shown to markedly influence the ability of different
antimicrobial agents to inhibit the formation of P. aeruginosa
biofilms. Significant differences in the efficacy of conventional
antibiotics (amikacin, colistin, gentamicin, and tobramycin) and
the antibiofilm peptide DJK-5 have been observed between
biofilms associated with 3-D lung epithelial cells and biofilms
formed on plastic surfaces (Crabbé et al., 2017). Interestingly,
the 3-D lung epithelial cell model offers the possibility to
assess in parallel the antibiofilm activity and the cytotoxicity
of antimicrobials toward cell types representative of the site of
infection. In the case of AMPs, the tendency to employ hemolytic
activity as preferred parameter for the high-throughput screening
of cytotoxicity has markedly limited the accurate evaluation
of their potential adverse effects. Indeed, the degree to which
AMPs permeabilize human erythrocytes may not realistically
reflect their selective toxicity against specific cell types in complex
biomatrices in vivo (Yeaman and Yount, 2003; Bacalum and
Radu, 2015). In addition to the lung environment, we aimed at
recreating the physiological conditions encountered in chronic
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FIGURE 5 | Biofilm-inhibitory activity of (lin-SB056-1)2-K (19.25 µM) against
CF isolates of P. aeruginosa in the 3-D lung epithelial cell model after 4 h of
incubation. Control (CTRL) represents untreated bacteria. Data are reported
as mean ± standard error of at least three independent experiments.
∗∗∗p < 0.001 (independent samples t-test or Mann–Whitney test).
wounds by employing an artificial dermis embedded in a blood-
based medium (Sun et al., 2008; Brackman et al., 2016). Despite
the absence of a biotic surface, the artificial wound model
closely reflects in vivo wound beds by resembling the nutritional
conditions found in wound exudates and the dermal surface
on which bacteria can adhere and form biofilm-like structures
(Brackman et al., 2016; Trivedi et al., 2017).
In a previous study, we have demonstrated the effectiveness
of the co-treatment with lin-SB056-1 and EDTA in preventing
P. aeruginosa biofilms in an abiotic environment similar to
the CF airway (Maisetta et al., 2017). Combination treatments
represent a promising strategy to enhance the efficacy of
AMPs against bacterial biofilms, especially under in vivo-like
conditions that are known to interfere with peptide activity
(Walkenhorst, 2016; Grassi et al., 2017b). In particular, the use
of the chelating agent EDTA has been shown to improve the
activity of different peptides due to its disaggregating effect on
the biofilm extracellular matrix and its perturbing action on the
outer membrane of Gram-negative bacteria (Banin et al., 2006;
Grassi et al., 2017c). Furthermore, the ability of EDTA to decrease
mucus viscosity has been hypothesized to promote the mobility
and killing activity of lin-SB056-1 in the presence of artificial
sputum (Gustafsson et al., 2012; Maisetta et al., 2017). In the
present study, the synergistic interaction between lin-SB056-1
and EDTA has also been confirmed in the 3-D lung epithelial cell
model. Indeed, lin-SB056-1 in combination with sub-inhibitory
concentrations of EDTA significantly reduced the formation of
P. aeruginosa biofilms in association with the airway epithelium.
In order to further improve the therapeutic potential of
lin-SB056-1, we investigated the antibiofilm properties of the
peptide’s dimeric derivative (lin-SB056-1)2-K in the same 3-
D lung infection model. Interestingly, (lin-SB056-1)2-K was
remarkably more effective than its monomeric counterpart in
preventing the formation of P. aeruginosa biofilm-like structures
in association with 3-D lung epithelial cells. Although in
agreement with peptides’ activity observed in GTSF-2, these
results contrast with MIC values obtained in MHB, where
(lin-SB056-1)2-K consistently exhibited MIC values higher than
lin-SB056-1 against both PAO1 strain and CF lung isolates
of P. aeruginosa. This observation indicates that medium
composition may greatly affect peptide activity, suggesting that
the widely used MHB might not be an appropriate medium
to screen the antibacterial potency of candidate AMPs (Dostert
et al., 2018). The significant difference between the MIC values
obtained in MHB and GTSF-2 could be due to differential peptide
binding to specific medium components, such as complex
carbohydrates (e.g., starch) that are present in MHB but not
in GTSF-2, and/or to proteins (Lelkes et al., 1997). Different
FIGURE 6 | Qualitative evaluation of the biofilm-inhibitory activity of (lin-SB056-1)2-K (19.25 µM) against GFP-expressing P. aeruginosa PAO1 in the 3-D lung
epithelial cell model after 4 h of incubation. Light microscopy (a,d), epifluorescence (b,e), and overlaid images (c,f) were obtained at a magnification of 599×. Scale
bar corresponds to 100 µm.
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FIGURE 7 | Biofilm-inhibitory activity of (lin-SB056-1)2-K (19.25 µM) against
P. aeruginosa PAO1 and wound clinical isolates in the in vitro artificial wound
model after 16 h of incubation. Control (CTRL) represents untreated bacteria.
Data are reported as mean ± standard error of at least three independent
experiments. ∗∗∗p < 0.001 (independent samples t-test).
amounts of cations and carbonate in these media could also
influence peptide activity in a manner that is difficult to forecast
(Dorschner et al., 2006; Wu et al., 2008).
It has been suggested that the concentration at which a peptide
exerts its antibiofilm activity is a parameter that could provide
valuable information about its mechanism of action (Batoni et al.,
2016a; Pletzer et al., 2016). Under the test conditions, both
lin-SB056-1 and (lin-SB056-1)2-K inhibited adhesion/biofilm
formation in association with host cells at concentrations equal
and/or higher than their MIC values in GTSF-2 medium, thereby
suggesting that they may act by a “classical” antibacterial effect
rather than via a biofilm-specific mechanism of action.
As expected, along with the enhancement of the biofilm-
inhibitory activity, dimerization of lin-SB056-1 led to an overall
increase in the cytotoxicity of the original peptide against both
3-D lung epithelial cells and human erythrocytes. An increase in
peptide cytotoxicity following modification is not surprising as it
is widely accepted that there is a direct relationship between the
antimicrobial and the cytotoxic properties of AMPs (Matsuzaki,
2009; Takahashi et al., 2010; Bolt et al., 2017). Nevertheless,
in the 3-D lung epithelial cell model, a net percentage of cell
death lower than 20% was observed at concentrations of (lin-
SB056-1)2-K that significantly inhibited biofilm formation (up to
1000-fold reduction in the number of biofilm-forming bacteria)
by both the reference strain PAO1 and two CF clinical isolates
of P. aeruginosa. Interestingly, when evaluated at the same cut-
off of cytotoxicity (20% cell death), (lin-SB056-1)2-K resulted in
a superior antibiofilm activity also compared to lin-SB056-1 used
in combination with EDTA, causing an additional reduction of 1
to 1.5-Log units in the CFU number as compared to the selected
lin-SB056-1/EDTA combinations (i.e., 19.25 µM lin-SB056-1 in
combination with 0.6 mM EDTA, and 38.5 µM lin-SB056-1 in
combination with 0.3 mM EDTA).
Overall, our findings underline the superiority of the
dendrimeric arrangement over the monomeric structure for
the maintenance of the antimicrobial activity in complex and
physiologically relevant environments. Interestingly, the biofilm-
inhibitory activity of (lin-SB056-1)2-K was also maintained
against different P. aeruginosa strains in the artificial wound
model under very challenging in vivo-like conditions due to
the presence of high concentrations of plasma/blood, which are
known to impact the activity of peptides (Maisetta et al., 2008).
It is commonly recognized that dendrimeric peptides exhibit
enhanced antimicrobial activity as compared to their monomeric
counterparts due to the higher local concentration of bioactive
units and the reduced susceptibility to proteolytic degradation
(Lind et al., 2015; Pires et al., 2015). In addition, it is likely
that (lin-SB056-1)2-K is less influenced than lin-SB056-1 by the
presence of physiological salt concentrations, as reported for
the original dimeric structure from which it was derived (i.e.,
den-SB056-1) (Batoni et al., 2016a).
Although (lin-SB056-1)2-K at the active concentrations
exhibited a certain degree of cytotoxicity against both
erythrocytes and lung epithelial cells, different strategies could be
exploited in the attempt to reduce peptide adverse effects against
mammalian cells, while maintaining its antimicrobial properties.
A number of different approaches have been described to control
cell selectivity of AMPs, including modulation of a range of
physicochemical parameters (e.g., hydrophobicity, helicity,
and amphipathicity), design of pro-peptides, and insertion
of D-amino acids and/or non-natural residues in the peptide
primary sequence (Matsuzaki, 2009; Takahashi et al., 2010; Forde
et al., 2016). Among these strategies, peptide entrapment in
suitable nanocarriers able to deliver the active molecules to the
infection site, while increasing their stability and minimizing
side effects, appears one of the most promising approaches, and
is currently under evaluation in our laboratory (Piras et al., 2015;
Sandreschi et al., 2016).
CONCLUSION
In order to narrow the gap between in vitro and in vivo
observations, research on AMPs should take into account the
influence of the host environment on biofilm phenotype and
peptide activity. Several studies have extensively questioned
the usefulness of currently performed antibiotic susceptibility
testing due to their limited clinical predictive value (Hurley
et al., 2012; Hancock, 2015; Coenye et al., 2018). Analysis of
antimicrobial activity in host-mimicking conditions represents
a convenient approach to make a more realistic prediction
of the therapeutic success of AMPs, thereby avoiding testing
unpromising peptides in costly animal studies and clinical
trials (Dorschner et al., 2006; Dostert et al., 2018). Although
clinical development of novel drugs requires evidence of in vivo
efficacy in animal models, preliminary in vitro evaluation in
physiologically relevant biofilm model systems may facilitate the
identification of effective AMP-based antimicrobials and reduce
animal testing. For instance, the ability of (lin-SB056-1)2-K to
preserve a significant antibiofilm activity in different challenging
host-mimicking environments suggested that such peptide might
be a promising template for the development of novel treatment
strategies against P. aeruginosa infections.
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